Global Next-Generation Breast Cancer Diagnostic and Screening Market

2.1    Scope of Work
2.2    Key Questions Answered in the Report

3.1    Primary Data Sources
3.2    Secondary Data Sources
3.3    Market Estimation Model

4.1    Introduction
4.2    Implementation of Precision Medicine in Breast Cancer Diagnostics
4.3    Impact of COVID-19 on Delivery of Care for Cancer Patients
4.4    Breast Cancer Clinical Trials

5.1    Overview
5.2    Impact Analysis
5.3    Market Drivers
         5.3.1    Increasing Prevalence of Breast Cancer Globally
         5.3.2    Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Breast Cancer
         5.3.3    Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis
5.4    Market Restraints
         5.4.1    Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
         5.4.2    Unavailability of High Capital Investment Hindering Expansion
         5.4.3    Issues Related to Clinical Validity of Biomarker-Based Tests
5.5    Market Opportunities
         5.5.1    Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
         5.5.2    Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
         5.5.3    Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan         

6.1    Key Strategies and Developments
         6.1.1    Product Approvals
         6.1.2    Product Launches and Upgradations
         6.1.3    Synergistic Activities
         6.1.4    Funding and Expansion
         6.1.5    Mergers and Acquisitions
         6.1.6    Other
6.2    Market Share Analysis (by Company), 2019
6.3    Growth Share Analysis (Opportunity Mapping)
         6.3.1    By Company

7.1    Overview
7.2    Real-Time PCR (q-PCR)
7.3    Immunohistochemistry (IHC)
7.4    Next-Generation Sequencing (NGS)
7.5    Fluorescent In-Situ Hybridization (FISH)
7.6    Other

8.1    Overview
8.2    Luminal A
8.3    Luminal B
8.4    Triple-Negative/Basal-Like
8.5    Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

9.1    Overview
9.2    BRCA Test
9.3    ER/PR Receptors
9.4    HER-2 Tests
9.5    Other

10.1    Overview
10.2    North America
           10.2.1    U.S.
           10.2.2    Canada
10.3    Europe
           10.3.1    Germany
           10.3.2    U.K.
           10.3.3    France
           10.3.4    Italy
           10.3.5    Spain
           10.3.6    Rest-of-Europe
10.4    Asia-Pacific
           10.4.1    China
           10.4.2    Japan
           10.4.3    India
           10.4.4    Australia
           10.4.5    Singapore
           10.4.6    Rest-of-APAC
10.5    Latin America
           10.5.1    Brazil
           10.5.2    Mexico
           10.5.3    Rest-of-Latin America
10.6    Rest-of-the-World

11.1    Overview
11.2    Hospital-associated Labs
11.3    Cancer Research Institutes
11.4    Diagnostic Centers
11.5    Other End Users

12.1    Overview
12.2    Abbott Laboratories
           12.2.1    Company Overview
           12.2.2    Role of Abbott Laboratories in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.2.3    Financials
                         12.2.3.1    Key Insights About Financial Health of the Company
           12.2.4    SWOT Analysis
12.3    Agendia
           12.3.1    Company Overview
           12.3.2    Role of Agendia in Next-Generation Breast Cancer Diagnostic and Screening Market
           12.3.3    SWOT Analysis
12.4    Agilent Technologies, Inc.
           12.4.1    Company Overview
           12.4.2    Role of Agilent Technologies, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.4.3    Financials
                         12.4.3.1    Key Insights About Financial Health of the Company
           12.4.4    SWOT Analysis
12.5    Ambry Genetics
           12.5.1    Company Overview
           12.5.2    Role of the Ambry Genetics in the Next-Generation Diagnostic and Screening Market
           12.5.3    SWOT Analysis
12.6    Biocept, Inc.
           12.6.1    Company Overview
           12.6.2    Role of Biocept, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.6.3    Financials
                         12.6.3.1    Key Insights About Financial Health of the Company
           12.6.4    SWOT Analysis
12.7    Biotheranostics, Inc.
           12.7.1    Company Overview
           12.7.2    Role of the Biotheranostics, Inc. in the Next-Generation Diagnostic and Screening Market
           12.7.3    SWOT Analysis
12.8    CENTOGENE N.V.
           12.8.1    Company Overview
           12.8.2    Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.8.3    Financials
                         12.8.3.1    Key Insights About Financial Health of the Company
           12.8.4    SWOT Analysis
12.9    Danaher Corporation
           12.9.1    Company Overview
           12.9.2    Role of Danaher Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.9.3    Financials
                         12.9.3.1    Key Insights About Financial Health of the Company
           12.9.4    SWOT Analysis
12.10  Exact Sciences Corporation
           12.10.1    Company Overview
           12.10.2    Role of Exact Sciences Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.10.3    Financials
                           12.10.3.1    Key Insights About Financial Health of the Company
           12.10.4    SWOT Analysis
12.11   F. Hoffmann-La Roche Ltd.
           12.11.1    Company Overview
           12.11.2    Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.11.3    Financials
                           12.11.3.1    Key Insights About Financial Health of the Company
           12.11.4    SWOT Analysis
12.12   Fulgent Genetics
           12.12.1    Company Overview
           12.12.2    Role of Fulgent Genetics in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.12.3    Financials
                           12.12.3.1    Key Insights About Financial Health of the Company
           12.12.4    SWOT Analysis
12.13    Illumina, Inc.
           12.13.1    Company Overview
           12.13.2    Role of Illumina, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.13.3    Financials
                           12.13.3.1    Key Insights about Financial Health of the Company
           12.13.4    SWOT Analysis
12.14   Invitae Corporation
           12.14.1    Company Overview
           12.14.2    Role of Invitae Corporation, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
           12.14.3    Financials
                           12.14.3.1    Key Insights About Financial Health of the Company
           12.14.4    SWOT Analysis
12.15  Lucence Diagnostics Pte Ltd
           12.15.1    Company Overview
           12.15.2    Role of the Lucene Diagnostic Pte Ltd in Next-Generation Breast Cancer Diagnostic and Screening Market
           12.15.3    SWOT Analysis
12.16  Myriad Genetics, Inc.
           12.16.1    Company Overview
           12.16.2    Role of Myriad Genetics, Inc. in the Next-Generation Breast Cancer Diagnostic Market
           12.16.3    Financials
                           12.16.3.1    Key Insights About Financial Health of the Company
           12.16.4    SWOT Analysis

Table 4.1:    Breast Cancer Clinical Trials
Table 5.1:    Likert Scale
Table 5.2:    Impact Analysis of Market Drivers
Table 5.3:    Impact Analysis of Market Restraints
Table 7.1:    Key Products Offered Based on RT-PCR
Table 7.2:    Key Products Offered Based on IHC
Table 7.3:    Key Products Offered Based on NGS
Table 7.4:    Key Products Offered Based on FISH
Table 7.5:    Key Products Offered Based on Other Technology
Table 9.1:    Key Products Offered Based on BRCA Test
Table 9.2:    Key Products Offered Based on ER/PR Test
Table 9.3:    Key Products Offered Based on HER-2

Figure 1:    Worldwide Breast Cancer Statistics (by Region), 2018
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the Next-Generation Breast Cancer Diagnostics and Screening Market
Figure 3:    Next-Generation Breast Cancer Diagnostics and Screening Market (by Product Type), ($Million), 2020 vs 2030
Figure 4:    Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2020 vs. 2030
Figure 5:    Next-GenerationNext-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2020 vs. 2030
Figure 6:    Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), ($Million), 2020 vs. 2030
Figure 7:    Next-Generation Breast Cancer Diagnostics and Screening Market Snapshot
Figure 2.1:    Next-Generation Breast Cancer Diagnostics and Screening Segmentation
Figure 3.1:    Primary Research Methodology
Figure 3.2:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3:    Top-Down Approach (Segment-Wise Analysis)
Figure 5.1:    Number of Cases (in Million) by Different Forms of Cancer, 2018
Figure 5.2:    Global Incidence of Breast Cancer Cases, As of 2018
Figure 6.1:    Share of Key Developments and Strategies, 2017-2020
Figure 6.2:    Product Approval Share (by Company), 2017–2020
Figure 6.3:    Product Launch and Upgradation Share (by Company), 2017–2020
Figure 6.4:    Synergistic Activities Share (by Company), 2017-2020
Figure 6.5:    Funding and Expansion Share (by Company), 2017-2020
Figure 6.6:    Mergers and Acquisitions Share (by Company), 2017-2020
Figure 6.7:    Other Key Development Share (by Company), 2017-2020
Figure 6.8:    Market Share Analysis for the Next-Generation Breast Cancer Diagnostics and Screening Market, 2019
Figure 6.9:    Growth Share Matrix for Next-Generation Breast Cancer Diagnostics and Screening (by Company), 2019
Figure 7.1:    Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2019-2030
Figure 7.2:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (RT-PCR), ($Million), 2019-2030
Figure 7.3:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (IHC), ($Million), 2019-2030
Figure 7.4:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (NGS), ($Million), 2019-2030
Figure 7.5:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (FISH), (($Million)), 2019-2030
Figure 7.6:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Other), 2019-2030 ($ Million)
Figure 8.1:    Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2019-2030
Figure 8.2:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal A), ($Million), 2019-2030
Figure 8.3:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal B), ($Million), 2019-2030
Figure 8.4:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Triple-negative/basal-like), ($Million), 2019-2030
Figure 8.5:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (by HER-2 Enriched), ($Million), 2019-2030
Figure 9.1:    Next-Generation Breast Cancer Diagnostic and Screening Market (by Test Type),($Million), 2019-2030
Figure 9.2:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (BRCA), ($Million), 2019-2030
Figure 9.3:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (ER/PR Receptor), ($Million), 2019-2030
Figure 9.4:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (HER-2), ($Million), 2019-2030
Figure 9.5:    Global Next-Generation Breast Cancer Diagnostics and Screening Market  (by Other), ($Million), 2019-2030
Figure 10.1:    Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2020 and 2030
Figure 10.2:    Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2019-2030
Figure 10.3:    North America Next-Generation Breast Cancer Diagnostic and Screening Market, (($Million)), 2019-2030
Figure 10.4:    North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.5:    North America: Market Dynamics
Figure 10.6:    U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.7:    Canada Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.8:    Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.9:    Europe: Market Dynamics
Figure 10.10:    Europe Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.11:    Germany Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.12:    U.K. Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.13:    France Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.14:    Italy Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.15:    Spain Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.16:    Rest-of-Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.17:    Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 10.18:    APAC: Market Dynamics
Figure 10.19:    APAC Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.20:    China Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.21:    Japan Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.22:    India Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.23:    Australia Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.24:    Singapore Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.25:    RoAPAC Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.26:    Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.27:    Latin America: Market Dynamics
Figure 10.28:    Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.29:    Brazil Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030,
Figure 10.30:    Mexico Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030,
Figure 10.31:    Rest-of-Latin America Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030
Figure 10.32:    RoW Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 11.1:    Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), ($Million), 2019-2030
Figure 11.2:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Hospital-associated labs), 2019-2030 ($ Million)
Figure 11.3:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Cancer Research Institutes), ($Million), 2019-2030
Figure 11.4:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (Diagnostic Centers), ($Million), 2019-2030
Figure 11.5:    Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other End Users), 2019-2030
Figure 12.1:    Total Number of Companies Profiled
Figure 12.2:    Abbott Laboratories: Portfolio
Figure 12.3:    Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.4:    Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 12.5:    Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 12.6:    Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 12.7:    Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 12.8:    Abbott Laboratories: SWOT Analysis
Figure 12.9:    Agendia: Product Portfolio
Figure 12.10:    Agendia: SWOT Analysis
Figure 12.11:    Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.12:    Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.13:    Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.14:    Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.15:    Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.16:    Agilent Technologies, Inc.: SWOT Analysis
Figure 12.17:    Ambry Genetics: Product portfolio
Figure 12.18:    Ambry Genetics: SWOT Analysis
Figure 12.19:    Biocept, Inc.: Portfolio
Figure 12.20:    Biocept, Inc.: Overall Financials, 2017-2019
Figure 12.21:    Biocept, Inc.: Sales (by Segment), 2017-2019
Figure 12.22:    Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 12.23:    Biocept, Inc.: SWOT Analysis
Figure 12.24:    Biotheranostics, Inc.: Product Portfolio
Figure 12.25:    Biotheranostics, Inc.: SWOT Analysis
Figure 12.26:    CENTOGENE N.V.: Overall Product Portfolio
Figure 12.27:    CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 12.28:    CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.29:    CENTOGENE N.V.: Sales (by Region), 2017-2019
Figure 12.30:    CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 12.31:    CENTOGENE N.V.: SWOT Analysis
Figure 12.32:    Danaher Corporation: Product Portfolio
Figure 12.33:    Danaher Corporation: Overall Financials, 2017-2019
Figure 12.34:    Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.35:    Danaher Corporation: Revenue (by Region), 2017-2019
Figure 12.36:    Danaher Corporation: R&D Expenditure, 2016-2018
Figure 12.37:    Danaher Corporation: SWOT Analysis
Figure 12.38:    Exact Science Corporation: Product Portfolio
Figure 12.39:    Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 12.40:    Exact Sciences Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.41:    Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 12.42:    Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 12.43:    Exact Sciences Corporation: SWOT Analysis
Figure 12.44:    F. Hoffmann-La Roche Ltd.: Portfolio
Figure 12.45:    F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
Figure 12.46:    F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2017-2019
Figure 12.47:    F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 12.48:    F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
Figure 12.49:    F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.50:    Fulgent Genetics: Product Portfolio
Figure 12.51:    Fulgent Genetics: Overall Financials, 2017-2019
Figure 12.52:    Fulgent Genetics: Revenue (by Business Segment), 2018-2019
Figure 12.53:    Fulgent Genetics: Revenue (by Region), 2017-2019
Figure 12.54:    Fulgent Genetics: R&D Expenditure, 2017-2019
Figure 12.55:    Fulgent Genetics: SWOT Analysis
Figure 12.56:    Illumina, Inc.: Portfolio
Figure 12.57:    Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.58:    Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.59:    Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.60:    Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.61:    Illumina, Inc.: SWOT Analysis
Figure 12.62:    Invitae Corporation: Overall Product Portfolio
Figure 12.63:    Invitae Corporation: Overall Financials, 2017-2019
Figure 12.64:    Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 12.65:    Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 12.66:    Invitae Corporation: R&D Expenditure, 2017-2019
Figure 12.67:    Invitae Corporation: SWOT Analysis
Figure 12.68:    Lucene Diagnostics Pte Ltd: Product Portfolio
Figure 12.69:    Lucene Diagnostic Pte Ltd: SWOT Analysis
Figure 12.70:    Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.71:    Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.72:    Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.73:    Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.74:    Myriad Genetics, Inc.: SWOT Analysis